review article | Q7318358 |
scholarly article | Q13442814 |
P356 | DOI | 10.1146/ANNUREV.IMMUNOL.23.021704.115707 |
P698 | PubMed publication ID | 15771584 |
P50 | author | Mireia Sospedra | Q61308810 |
Roland Martin | Q69171707 | ||
P921 | main subject | multiple sclerosis | Q8277 |
immunology | Q101929 | ||
P304 | page(s) | 683-747 | |
P577 | publication date | 2005-01-01 | |
P1433 | published in | Annual Review of Immunology | Q567362 |
P1476 | title | Immunology of multiple sclerosis | |
P478 | volume | 23 |
Q34091080 | 'Multi-epitope-targeted' immune-specific therapy for a multiple sclerosis-like disease via engineered multi-epitope protein is superior to peptides |
Q37776167 | A Consensus Statement Addressing Mesenchymal Stem Cell Transplantation for Multiple Sclerosis: It’s Time! |
Q36984189 | A Diet Mimicking Fasting Promotes Regeneration and Reduces Autoimmunity and Multiple Sclerosis Symptoms |
Q50886047 | A Nanobiosensor Based on Fluorescent DNA-Hosted Silver Nanocluster and HCR Amplification for Detection of MicroRNA Involved in Progression of Multiple Sclerosis. |
Q36635131 | A Urinary Metabolic Signature for Multiple Sclerosis and Neuromyelitis Optica |
Q33367112 | A beta-lactam antibiotic dampens excitotoxic inflammatory CNS damage in a mouse model of multiple sclerosis |
Q33857396 | A critical role for virus-specific CD8(+) CTLs in protection from Theiler's virus-induced demyelination in disease-susceptible SJL mice |
Q42767100 | A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. |
Q38258366 | A method for histopathological study of the multifocal nature of spinal cord lesions in murine experimental autoimmune encephalomyelitis. |
Q30723942 | A molecular view of multiple sclerosis and experimental autoimmune encephalitis: what can we learn from the epitope data? |
Q33306704 | A network analysis of the human T-cell activation gene network identifies JAGGED1 as a therapeutic target for autoimmune diseases |
Q36494088 | A new humanized HLA transgenic mouse model of multiple sclerosis expressing class II on mouse CD4 T cells. |
Q61445020 | A novel neurotherapeutic for multiple sclerosis, ischemic injury, methamphetamine addiction, and traumatic brain injury |
Q35790269 | A study of experimental autoimmune encephalomyelitis in dogs as a disease model for canine necrotizing encephalitis |
Q28256953 | A tale of two citrullines--structural and functional aspects of myelin basic protein deimination in health and disease |
Q34518133 | Absence of IFN-γ increases brain pathology in experimental autoimmune encephalomyelitis-susceptible DRB1*0301.DQ8 HLA transgenic mice through secretion of proinflammatory cytokine IL-17 and induction of pathogenic monocytes/microglia into the centra |
Q34639949 | Accounting for eXentricities: analysis of the X chromosome in GWAS reveals X-linked genes implicated in autoimmune diseases |
Q33930062 | Act1 mediates IL-17-induced EAE pathogenesis selectively in NG2+ glial cells |
Q34986269 | Activation of endogenous neural stem cells for multiple sclerosis therapy |
Q81122390 | Activation of myelin reactive T cells in multiple sclerosis: a possible role for T cell degeneracy? |
Q35230209 | Activation of p38 MAPK in CD4 T cells controls IL-17 production and autoimmune encephalomyelitis |
Q48175463 | Active induction of experimental allergic encephalomyelitis |
Q37227771 | Acute disseminated encephalomyelitis: clinical and pathogenesis features. |
Q35112101 | Administration of chinpi, a component of the herbal medicine ninjin-youei-to, reverses age-induced demyelination |
Q33263472 | Age-related macular degeneration--emerging pathogenetic and therapeutic concepts |
Q35101760 | Agent based modeling of Treg-Teff cross regulation in relapsing-remitting multiple sclerosis |
Q39470133 | Agent-based modeling of the immune system: NetLogo, a promising framework |
Q37321172 | Akt1 is critical for acute inflammation and histamine-mediated vascular leakage |
Q42361890 | Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world |
Q43073589 | Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months. |
Q33701762 | Allopregnanolone and neuroinflammation: a focus on multiple sclerosis |
Q41595215 | Altered T cell phenotypes associated with clinical relapse of multiple sclerosis patients receiving fingolimod therapy |
Q36428498 | Alternative source of stem cells derived from human periodontal ligament: a new treatment for experimental autoimmune encephalomyelitis |
Q45373997 | Ameliorating effects of anti-Dll4 mAb on Theiler's murine encephalomyelitis virus-induced demyelinating disease |
Q55244957 | Amelioration of Experimental autoimmune encephalomyelitis and DSS induced colitis by NTG-A-009 through the inhibition of Th1 and Th17 cells differentiation. |
Q28732434 | Amelioration of experimental autoimmune encephalomyelitis in C57BL/6 mice by photobiomodulation induced by 670 nm light |
Q37311315 | An immunomodulating motif of the HIV-1 fusion protein is chirality-independent: implications for its mode of action |
Q40152964 | An increase in tolerogenic dendritic cell and natural regulatory T cell numbers during experimental autoimmune encephalomyelitis in Rras-/- mice results in attenuated disease. |
Q34499810 | Angiogenesis is present in experimental autoimmune encephalomyelitis and pro-angiogenic factors are increased in multiple sclerosis lesions |
Q38396248 | Animal models of Multiple Sclerosis. |
Q38882149 | Anti-Inflammatory Effect of Wogonin on RAW 264.7 Mouse Macrophages Induced with Polyinosinic-Polycytidylic Acid. |
Q28080791 | Antigen Presentation, Autoantigens, and Immune Regulation in Multiple Sclerosis and Other Autoimmune Diseases |
Q36512334 | Antigen-induced Pten gene deletion in T cells exacerbates neuropathology in experimental autoimmune encephalomyelitis |
Q37679881 | Antigen-specific tolerance by autologous myelin peptide-coupled cells: a phase 1 trial in multiple sclerosis |
Q35671182 | Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor). |
Q37324056 | Astrocyte, the star avatar: redefined. |
Q34777465 | Astrocyte-restricted ablation of interleukin-17-induced Act1-mediated signaling ameliorates autoimmune encephalomyelitis |
Q24628925 | Atacicept: targeting B cells in multiple sclerosis |
Q99573638 | Attenuated immune control of Epstein Barr virus in humanized mice is associated with the multiple sclerosis risk factor HLA-DR15 |
Q83293324 | Autoantibodies to myelin basic protein (MBP) in healthy individuals and in patients with multiple sclerosis: a role in regulating cytokine responses to MBP |
Q33992633 | Autoantibodies to myelin basic protein catalyze site-specific degradation of their antigen |
Q35214738 | Autoantibody-mediated demyelination depends on complement activation but not activatory Fc-receptors |
Q36007039 | Autoantigen conformation influences both B- and T-cell responses and encephalitogenicity |
Q50485184 | Autoimmune animal models in the analysis of the CD47-SIRPα signaling pathway. |
Q36657652 | Autoimmune modulation of astrocyte-mediated homeostasis. |
Q37667281 | Autophagy and Autophagy-Related Proteins in CNS Autoimmunity. |
Q34686890 | Autophagy, inflammation and neurodegenerative disease |
Q37006059 | Autoreactive Tbet-positive CD4 T cells develop independent of classic Th1 cytokine signaling during experimental autoimmune encephalomyelitis |
Q37743241 | Axo-glial antigens as targets in multiple sclerosis: implications for axonal and grey matter injury. |
Q37313740 | B cell-derived IL-15 enhances CD8 T cell cytotoxicity and is increased in multiple sclerosis patients |
Q35903957 | B cells and autoantibodies in the pathogenesis of multiple sclerosis and related inflammatory demyelinating diseases |
Q34544062 | B cells move to centre stage: novel opportunities for autoimmune disease treatment |
Q37679878 | B7-H4Ig inhibits mouse and human T-cell function and treats EAE via IL-10/Treg-dependent mechanisms |
Q37671295 | BJ-1108, a 6-Amino-2,4,5-trimethylpyridin-3-ol analogue, regulates differentiation of Th1 and Th17 cells to ameliorate experimental autoimmune encephalomyelitis |
Q26744116 | Big data to smart data in Alzheimer's disease: Real-world examples of advanced modeling and simulation |
Q47099956 | Bioactivity of Olive Oil Phenols in Neuroprotection. |
Q42789516 | Biological outcome measurements for behavioral interventions in multiple sclerosis |
Q26827146 | Biphasic mechanisms of neurovascular unit injury and protection in CNS diseases |
Q36516815 | Blocking A2B adenosine receptor alleviates pathogenesis of experimental autoimmune encephalomyelitis via inhibition of IL-6 production and Th17 differentiation |
Q38984981 | Blood Biomarkers as Outcome Measures in Inflammatory Neurologic Diseases |
Q37193914 | Blood RNA profiling in a large cohort of multiple sclerosis patients and healthy controls |
Q35078327 | Body fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the future |
Q64058668 | Brain Citrullination Patterns and T Cell Reactivity of Cerebrospinal Fluid-Derived CD4 T Cells in Multiple Sclerosis |
Q82810101 | Brain antigens in functionally distinct antigen-presenting cell populations in cervical lymph nodes in MS and EAE |
Q26865295 | Brain innate immunity in the regulation of neuroinflammation: therapeutic strategies by modulating CD200-CD200R interaction involve the cannabinoid system |
Q48407284 | Brain protection conferred by long-term administration of 2-(2-benzofuranyl)-2-imidazoline against experimental autoimmune encephalomyelitis |
Q35458567 | Brain-reactive antibodies and disease. |
Q45936271 | Brazilian experience with two conditioning regimens in patients with multiple sclerosis: BEAM/horse ATG and CY/rabbit ATG. |
Q36299109 | Broad spectrum immune monitoring in immune-mediated inflammatory disorders |
Q92531242 | Butyrate suppresses demyelination and enhances remyelination |
Q35894777 | Bystander-mediated stimulation of proteolipid protein-specific regulatory T (Treg) cells confers protection against experimental autoimmune encephalomyelitis (EAE) via TGF-β. |
Q80455478 | CD28:B7 interaction is necessary for the protective effect of T cell vaccination in EAE |
Q37061386 | CD4 T cells: Balancing the coming and going of autoimmune-mediated inflammation in the CNS. |
Q38732306 | CD4+ T-cell subsets in inflammatory diseases: beyond the Th1/Th2 paradigm |
Q37365433 | CD40 and autoimmunity: the dark side of a great activator. |
Q34361334 | CNS-specific expression of C3a and C5a exacerbate demyelination severity in the cuprizone model |
Q35571261 | CSF Proteomics Identifies Specific and Shared Pathways for Multiple Sclerosis Clinical Subtypes |
Q38779104 | CXCR3 signaling in glial cells ameliorates experimental autoimmune encephalomyelitis by restraining the generation of a pro-Th17 cytokine milieu and reducing CNS-infiltrating Th17 cells |
Q64069827 | Calling in the Caalry- Hijacks GABAergic Signaling and Voltage-Dependent Calcium Channel Signaling for -Mediated Dissemination |
Q37237452 | Calpain-mediated signaling mechanisms in neuronal injury and neurodegeneration |
Q81478365 | Cannabinoids and multiple sclerosis |
Q39119286 | Cannabinoids decrease the th17 inflammatory autoimmune phenotype |
Q37316510 | Carcinoembryonic antigen-related cell adhesion molecule 1 modulates experimental autoimmune encephalomyelitis via an iNKT cell-dependent mechanism |
Q31130538 | Cardiac Safety Profile of First Dose of Fingolimod for Relapsing-Remitting Multiple Sclerosis in Real-World Settings: Data from a German Prospective Multi-Center Observational Study |
Q36089786 | Cell death of spinal cord ED1(+) cells in a rat model of multiple sclerosis. |
Q34056814 | Cell replacement therapies to promote remyelination in a viral model of demyelination |
Q57491432 | Cell-Mediated Immune Responses and Immunopathogenesis of Human Tick-Borne Encephalitis Virus-Infection |
Q36416627 | Cellular sources of dysregulated cytokines in relapsing-remitting multiple sclerosis |
Q50984358 | Central nervous system recruitment of effector memory CD8+ T lymphocytes during neuroinflammation is dependent on α4 integrin. |
Q36072420 | Central role of Th2/Tc2 lymphocytes in pattern II multiple sclerosis lesions |
Q21144285 | Cerebrospinal fluid B cells correlate with early brain inflammation in multiple sclerosis |
Q33912628 | Cerebrospinal fluid secretory Ca2+-dependent phospholipase A2 activity: a biomarker of blood-cerebrospinal fluid barrier permeability |
Q91734156 | Changes of B cell subsets in central pathological process of autoimmune encephalomyelitis in mice |
Q52566925 | Characterization of Transglutaminase 2 activity inhibitors in monocytes in vitro and their effect in a mouse model for multiple sclerosis. |
Q34232425 | Characterization of oligodendroglial populations in mouse demyelinating disease using flow cytometry: clues for MS pathogenesis |
Q54285111 | Characterization of the interaction between astrocytes and encephalitogenic lymphocytes during the development of experimental autoimmune encephalitomyelitis (EAE) in mice. |
Q28478279 | Charge isomers of myelin basic protein: structure and interactions with membranes, nucleotide analogues, and calmodulin |
Q33994547 | Chemokine-like receptor-1 expression by central nervous system-infiltrating leukocytes and involvement in a model of autoimmune demyelinating disease |
Q37055339 | Chronic exposure to water pollutant trichloroethylene increased epigenetic drift in CD4(+) T cells |
Q33797172 | Chronic restraint stress during early Theiler's virus infection exacerbates the subsequent demyelinating disease in SJL mice: II. CNS disease severity |
Q58115047 | Circulating EZH2-positive T cells are decreased in multiple sclerosis patients |
Q49165904 | Circulating exosomes suppress the induction of regulatory T cells via let-7i in multiple sclerosis |
Q33535660 | Cleavage of transaldolase by granzyme B causes the loss of enzymatic activity with retention of antigenicity for multiple sclerosis patients |
Q38070677 | Clinical testing for neutralizing antibodies to interferon-β in multiple sclerosis |
Q47225588 | Co-Transplantation of Human Neurotrophic Factor Secreting Cells and Adipose-Derived Stem Cells in Rat Model of Multiple Sclerosis |
Q35166937 | Combination treatment of mice with CRx-153 (nortriptyline and desloratadine) decreases the severity of experimental autoimmune encephalomyelitis |
Q97067655 | Comparative Analysis of T-Cell Responses to Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein in Inflammatory Demyelinating Central Nervous System Diseases |
Q50239453 | Comparative Neuroregenerative Effects of C-Phycocyanin and IFN-Beta in a Model of Multiple Sclerosis in Mice |
Q57296139 | Comparative transcriptomic profile of tolerogenic dendritic cells differentiated with vitamin D3, dexamethasone and rapamycin |
Q81356139 | Compromised CD4+ CD25(high) regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the single-cell level |
Q26774368 | Computational Modelling Approaches on Epigenetic Factors in Neurodegenerative and Autoimmune Diseases and Their Mechanistic Analysis |
Q57062331 | Computational comparison of two new fusion proteins for multiple sclerosis |
Q37208572 | Contactin-2/TAG-1-directed autoimmunity is identified in multiple sclerosis patients and mediates gray matter pathology in animals |
Q37313736 | Contribution of CD8 T lymphocytes to the immuno-pathogenesis of multiple sclerosis and its animal models. |
Q36267838 | Control of IL-17 receptor signaling and tissue inflammation by the p38α-MKP-1 signaling axis in a mouse model of multiple sclerosis |
Q47892707 | Controlled Release of Second Generation mTOR Inhibitors to Restrain Inflammation in Primary Immune Cells |
Q48241189 | Cortical atrophy is relevant in multiple sclerosis at clinical onset. |
Q54261778 | Critical Roles of IL-33/ST2 Pathway in Neurological Disorders. |
Q80584784 | Critical regulation of CD4+ T cell survival and autoimmunity by beta-arrestin 1 |
Q36634895 | Critical role of activation induced cytidine deaminase in experimental autoimmune encephalomyelitis. |
Q27680393 | Crossreactivity of a human autoimmune TCR is dominated by a single TCR loop |
Q36789308 | Crosstalk between endocannabinoid and immune systems: a potential dysregulation in depression? |
Q56573336 | Crucial role of interleukin-7 in T helper type 17 survival and expansion in autoimmune disease |
Q92444762 | Csf1 Deficiency Dysregulates Glial Responses to Demyelination and Disturbs CNS White Matter Remyelination |
Q35495245 | Cuprizone-induced demyelination and demyelination-associated inflammation result in different proton magnetic resonance metabolite spectra |
Q37793141 | Current and Future Role of Interferon Beta in the Therapy of Multiple Sclerosis |
Q36827362 | Current concepts of the cellular and molecular pathophysiology of multiple sclerosis |
Q38911206 | Current multiple sclerosis treatments have improved our understanding of MS autoimmune pathogenesis |
Q34095225 | Current views on the roles of Th1 and Th17 cells in experimental autoimmune encephalomyelitis |
Q38751579 | Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system |
Q35613492 | Cutting edge: loss of α4 integrin expression differentially affects the homing of Th1 and Th17 cells |
Q33863351 | Cyclooxygenase-2 expression in oligodendrocytes increases sensitivity to excitotoxic death |
Q28534321 | Cyclotides Suppress Human T-Lymphocyte Proliferation by an Interleukin 2-Dependent Mechanism |
Q52143402 | Cytokine Profile in Patients with Progressive Multiple Sclerosis and Its Association with Disease Progression and Disability. |
Q42363220 | Cytotoxic CD4+ T Cells Drive Multiple Sclerosis Progression. |
Q35935131 | DQB1*0602 rather than DRB1*1501 confers susceptibility to multiple sclerosis-like disease induced by proteolipid protein (PLP). |
Q34349507 | DQB1*06:02-Associated Pathogenic Anti-Myelin Autoimmunity in Multiple Sclerosis-Like Disease: Potential Function of DQB1*06:02 as a Disease-Predisposing Allele |
Q37145510 | Decreased T cell reactivity to Epstein-Barr virus infected lymphoblastoid cell lines in multiple sclerosis. |
Q33920152 | Deficiency of the G protein Gαq ameliorates experimental autoimmune encephalomyelitis with impaired DC-derived IL-6 production and Th17 differentiation |
Q34574703 | Deimination of membrane-bound myelin basic protein in multiple sclerosis exposes an immunodominant epitope |
Q34428400 | Deletion of IL-33R (ST2) abrogates resistance to EAE in BALB/C mice by enhancing polarization of APC to inflammatory phenotype |
Q33838749 | Design and Synthesis of Non-Peptide Mimetics Mapping the Immunodominant Myelin Basic Protein (MBP83-96) Epitope to Function as T-Cell Receptor Antagonists. |
Q54937236 | Detailed Characterization of T Cell Receptor Repertoires in Multiple Sclerosis Brain Lesions. |
Q91576425 | Deubiquitinating enzymes (DUBs): DoUBle-edged swords in CNS autoimmunity |
Q33582690 | Development and Pre-Clinical Evaluation of Recombinant Human Myelin Basic Protein Nano Therapeutic Vaccine in Experimental Autoimmune Encephalomyelitis Mice Animal Model. |
Q92149773 | Diagnostic Considerations in Acute Disseminated Encephalomyelitis and the Interface with MOG Antibody |
Q42030864 | Different mechanisms of inflammation induced in virus and autoimmune-mediated models of multiple sclerosis in C57BL6 mice. |
Q38664253 | Differential effects of FTY720 on the B cell compartment in a mouse model of multiple sclerosis. |
Q37093197 | Differential induction of experimental autoimmune encephalomyelitis by myelin basic protein molecular mimics in mice humanized for HLA-DR2 and an MBP(85-99)-specific T cell receptor |
Q41832065 | Differential outcome of tolerance induction in naive versus activated Theiler's virus epitope-specific CD8+ cytotoxic T cells |
Q33619976 | Differential regulation of central nervous system autoimmunity by T(H)1 and T(H)17 cells. |
Q54209318 | Differing Outcome of Experimental Autoimmune Encephalitis in Macrophage/Neutrophil- and T Cell-Specific gp130-Deficient Mice. |
Q41771263 | Diffusion Tensor Imaging in NAWM and NADGM in MS and CIS: Association with Candidate Biomarkers in Sera |
Q57814499 | Dimethyl fumarate as a first- vs second-line therapy in MS: Focus on B cells |
Q61479730 | Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells |
Q36416340 | Direct suppression of autoreactive lymphocytes in the central nervous system via the CB2 receptor |
Q36300489 | Discovery of BVDU as a promising Drug for autoimmune diseases Therapy by Dendritic-cell-based functional screening |
Q34151104 | Discrepancy in CCL2 and CCR2 expression in white versus grey matter hippocampal lesions of Multiple Sclerosis patients |
Q33625425 | Disease exacerbation of multiple sclerosis is characterized by loss of terminally differentiated autoregulatory CD8+ T cells. |
Q37328280 | Disease-modifying agents for multiple sclerosis: recent advances and future prospects |
Q38137114 | Disease-modifying therapy in multiple sclerosis and chronic inflammatory demyelinating polyradiculoneuropathy: common and divergent current and future strategies |
Q42094299 | Disruption of the beta2-integrin CD11d (alphaDbeta2) gene fails to protect against experimental autoimmune encephalomyelitis |
Q36314027 | Does the Gut Microbiota Influence Immunity and Inflammation in Multiple Sclerosis Pathophysiology? |
Q36577212 | Drug insight: using monoclonal antibodies to treat multiple sclerosis |
Q46036987 | Dual role of Response gene to complement-32 in multiple sclerosis. |
Q61445603 | Dynamic changes of MMP-9 plasma levels correlate with JCV reactivation and immune activation in natalizumab-treated multiple sclerosis patients |
Q34687561 | Dynamic cross-regulation of antigen-specific effector and regulatory T cell subpopulations and microglia in brain autoimmunity |
Q48178994 | Dysregulated RNA-Induced Silencing Complex (RISC) Assembly within CNS Corresponds with Abnormal miRNA Expression during Autoimmune Demyelination. |
Q37578372 | EAE: an immunologist's magic eye. |
Q40543886 | EBV and vitamin D status in relapsing-remitting multiple sclerosis patients with a unique cytokine signature. |
Q42322167 | Editorial: Lymphocytes in MS and EAE: More Than Just a CD4+ World |
Q38636586 | Effectiveness, safety and health-related quality of life of multiple sclerosis patients treated with fingolimod: results from a 12-month, real-world, observational PERFORMS study in the Middle East. |
Q41951909 | Effector and suppressor roles for LFA-1 during the development of experimental autoimmune encephalomyelitis |
Q41020615 | Effects of IFN-β1a and IFN-β1b treatment on the expression of cytokines, inducible NOS (NOS type II), and myelin proteins in animal model of multiple sclerosis. |
Q55516350 | Effects of Systolic Blood Pressure on Brain Integrity in Multiple Sclerosis. |
Q34475830 | Effects of coenzyme Q10 on the ratio of TH1/TH2 in experimental autoimmune encephalomyelitis model of multiple sclerosis in C57BL/6. |
Q35082644 | Effects of early IL-17A neutralization on disease induction in a primate model of experimental autoimmune encephalomyelitis |
Q37261686 | Effects of vaccination with altered Peptide ligand on chronic pain in experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis |
Q34712554 | Effects on immune cells of a new 1,8-naphthyridin-2-one derivative and its analogues as selective CB2 agonists: implications in multiple sclerosis |
Q36298955 | Elevated type I interferon-like activity in a subset of multiple sclerosis patients: molecular basis and clinical relevance |
Q37412980 | Eliminating encephalitogenic T cells without undermining protective immunity |
Q37809764 | Emerging topics and new perspectives on HLA-G. |
Q37991266 | End-point effector stress mediators in neuroimmune interactions: their role in immune system homeostasis and autoimmune pathology. |
Q35146806 | Endogenous interferon-β-inducible gene expression and interferon-β-treatment are associated with reduced T cell responses to myelin basic protein in multiple sclerosis. |
Q22252381 | Environmental factors and their regulation of immunity in multiple sclerosis |
Q34041828 | Environmental factors in early childhood are associated with multiple sclerosis: a case-control study |
Q36145913 | Eomesodermin-expressing T-helper cells are essential for chronic neuroinflammation |
Q47140915 | Epigallocatechin-3-gallate ameliorates experimental autoimmune encephalomyelitis by altering balance among CD4+ T-cell subsets |
Q27010680 | Epistasis and immunity: the role of genetic interactions in autoimmune diseases |
Q36414419 | Epitope-specific CD8+ T cells play a differential pathogenic role in the development of a viral disease model for multiple sclerosis |
Q35697927 | Epstein-Barr Virus Specific Antibody Response in Multiple Sclerosis Patients during 21 Months of Natalizumab Treatment. |
Q55982210 | Epstein-Barr virus and multiple sclerosis |
Q30878158 | Epstein-Barr virus and multiple sclerosis: potential opportunities for immunotherapy |
Q26830464 | Epstein-Barr virus in systemic lupus erythematosus, rheumatoid arthritis and multiple sclerosis—association and causation |
Q35914342 | Epstein-barr virus: environmental trigger of multiple sclerosis? |
Q34610594 | Estrogen and testosterone therapies in multiple sclerosis |
Q36778684 | Estrogen induces multiple regulatory B cell subtypes and promotes M2 microglia and neuroprotection during experimental autoimmune encephalomyelitis |
Q46325643 | Estrogen protection against EAE modulates the microbiota and mucosal-associated regulatory cells. |
Q37130888 | Evaluating epigenetic landmarks in the brain of multiple sclerosis patients: a contribution to the current debate on disease pathogenesis |
Q36474367 | Evidence for humoral autoimmunity in neuromyelitis optica |
Q61971664 | Evolution of MS lesions to black holes under DNA vaccine treatment |
Q33770508 | Expanding Role of T Cells in Human Autoimmune Diseases of the Central Nervous System |
Q50114920 | Experimental Autoimmune Encephalomyelitis (EAE) as Animal Models of Multiple Sclerosis (MS). |
Q35589934 | Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). |
Q35563492 | Experimental autoimmune encephalomyelitis development is aggravated by Candida albicans infection |
Q36845899 | Experimental optic neuritis induced by a demyelinating strain of mouse hepatitis virus. |
Q38361889 | Exploring the origins of grey matter damage in multiple sclerosis. |
Q37711026 | Exploring the roles of CD8(+) T lymphocytes in the pathogenesis of autoimmune demyelination |
Q91725700 | Expression of CD1d by astrocytes corresponds with relative activity in multiple sclerosis lesions |
Q34149191 | Expression of IL-33 and its epigenetic regulation in Multiple Sclerosis |
Q58720899 | Expression of the neuroprotective protein aryl hydrocarbon receptor nuclear translocator 2 correlates with neuronal stress and disability in models of multiple sclerosis |
Q90618608 | Extended treatment with fingolimod for relapsing multiple sclerosis: the 14-year LONGTERMS study results |
Q52926000 | Extracellular Vesicles in Multiple Sclerosis as Possible Biomarkers: Dream or Reality? |
Q28074658 | Fas-Fas Ligand: Checkpoint of T Cell Functions in Multiple Sclerosis |
Q44516794 | Fasudil ameliorates disease progression in experimental autoimmune encephalomyelitis, acting possibly through antiinflammatory effect |
Q35052362 | Fingolimod (FTY720): First approved oral therapy for multiple sclerosis |
Q21195861 | Fluids and barriers of the CNS establish immune privilege by confining immune surveillance to a two-walled castle moat surrounding the CNS castle |
Q37071856 | Fn14-TRAIL, a chimeric intercellular signal exchanger, attenuates experimental autoimmune encephalomyelitis. |
Q48442984 | Frequency of current utilisation of complementary and alternative medicine by patients with multiple sclerosis |
Q37483492 | From genes to function: the next challenge to understanding multiple sclerosis |
Q34571353 | Functional epistasis on a common MHC haplotype associated with multiple sclerosis |
Q42318115 | Functional genomics analysis of vitamin D effects on CD4+ T cells in vivo in experimental autoimmune encephalomyelitis . |
Q35986699 | Functional identification of pathogenic autoantibody responses in patients with multiple sclerosis |
Q36990042 | Fundamental differences in the dynamics of CNS lesion development and composition in MP4- and MOG peptide 35-55-induced experimental autoimmune encephalomyelitis |
Q37112554 | G protein-coupled receptors as therapeutic targets for multiple sclerosis |
Q47975519 | Gaining entry to an uninflamed brain |
Q33725068 | Gammadelta T cells in EAE: early trafficking events and cytokine requirements |
Q34277058 | Gammaherpesvirus latency accentuates EAE pathogenesis: relevance to Epstein-Barr virus and multiple sclerosis. |
Q57061847 | Gelatinase B/matrix metalloproteinase-9 is a phase-specific effector molecule, independent from Fas, in experimental autoimmune encephalomyelitis |
Q34659651 | Genetic association of rs1520333 G/A polymorphism in the IL7 gene with multiple sclerosis susceptibility in Isfahan population |
Q33890981 | Genetic deficiency of Irgm1 (LRG-47) suppresses induction of experimental autoimmune encephalomyelitis by promoting apoptosis of activated CD4+ T cells |
Q36866321 | Genetic variants in the immunoglobulin heavy chain locus are associated with the IgG index in multiple sclerosis |
Q51415619 | Genomic Effects of the Vitamin D Receptor: Potentially the Link between Vitamin D, Immune Cells, and Multiple Sclerosis. |
Q37165875 | Getting specific: monoclonal antibodies in multiple sclerosis. |
Q36440629 | Glial toll-like receptor signaling in central nervous system infection and autoimmunity |
Q37029694 | Glucocorticoid exposure alters the pathogenesis of Theiler's murine encephalomyelitis virus during acute infection |
Q26853743 | Glucocorticoids and endothelial cell barrier function |
Q36210121 | Gray Matter Hypoxia in the Brain of the Experimental Autoimmune Encephalomyelitis Model of Multiple Sclerosis |
Q26863405 | Gut commensalism, cytokines, and central nervous system demyelination |
Q50097667 | Gut dysbiosis breaks immunological tolerance toward the central nervous system during young adulthood. |
Q79803676 | HLA class I: friend and foe of multiple sclerosis |
Q36958285 | HLA-DQ6 (DQB1*0601)-restricted T cells protect against experimental autoimmune encephalomyelitis in HLA-DR3.DQ6 double-transgenic mice by generating anti-inflammatory IFN-gamma |
Q37151283 | HLA-DQ8 (DQB1*0302)-restricted Th17 cells exacerbate experimental autoimmune encephalomyelitis in HLA-DR3-transgenic mice. |
Q35782781 | HLA-DRα1-mMOG-35-55 treatment of experimental autoimmune encephalomyelitis reduces CNS inflammation, enhances M2 macrophage frequency, and promotes neuroprotection |
Q48445330 | Haptoglobin deficiency facilitates the development of autoimmune inflammation. |
Q36283450 | Heat shock protein 70: roles in multiple sclerosis |
Q40119805 | Helminth Products Potently Modulate Experimental Autoimmune Encephalomyelitis by Downregulating Neuroinflammation and Promoting a Suppressive Microenvironment. |
Q33965239 | Hematopoietic stem cell transplantation for multiple sclerosis: collaboration of the CIBMTR and EBMT to facilitate international clinical studies |
Q35589270 | Heme oxygenase-1 and carbon monoxide suppress autoimmune neuroinflammation |
Q57898104 | Hemoglobin as a source of iron overload in multiple sclerosis: does multiple sclerosis share risk factors with vascular disorders? |
Q33778883 | Hepatocyte growth factor inhibits CNS autoimmunity by inducing tolerogenic dendritic cells and CD25+Foxp3+ regulatory T cells |
Q52720499 | Heritability enrichment of specifically expressed genes identifies disease-relevant tissues and cell types. |
Q36778303 | High-Density Peptide Microarray Analysis of IgG Autoantibody Reactivities in Serum and Cerebrospinal Fluid of Multiple Sclerosis Patients. |
Q38058619 | Hormone and immune system interactions in demyelinating disease |
Q34170760 | Hsp70 and its molecular role in nervous system diseases |
Q40275029 | Human Epistatic Interaction Controls IL7R Splicing and Increases Multiple Sclerosis Risk. |
Q58571221 | Human Induced Pluripotent Stem Cell-Derived Astrocytes Are Differentially Activated by Multiple Sclerosis-Associated Cytokines |
Q41487863 | Human Leukocyte Antigen (HLA)-DRB1*15:01 and HLA-DRB5*01:01 Present Complementary Peptide Repertoires |
Q34683399 | Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation |
Q37253314 | Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis. |
Q35586871 | Human brain endothelial cells endeavor to immunoregulate CD8 T cells via PD-1 ligand expression in multiple sclerosis |
Q37778884 | Human endogenous retroviruses and multiple sclerosis: innocent bystanders or disease determinants? |
Q51765773 | ICOS deficiency results in exacerbated IL-17 mediated experimental autoimmune encephalomyelitis. |
Q36417195 | IFN-γ limits Th9-mediated autoimmune inflammation through dendritic cell modulation of IL-27 |
Q36509839 | IFNAR signaling directly modulates T lymphocyte activity, resulting in milder experimental autoimmune encephalomyelitis development |
Q59854924 | IL-10 suppressor activity andex vivo Tr1 cell function are impaired in multiple sclerosis |
Q37008475 | IL-13 production by regulatory T cells protects against experimental autoimmune encephalomyelitis independently of autoantigen |
Q37865163 | IL-17 receptor signaling and T helper 17-mediated autoimmune demyelinating disease |
Q36142154 | IL-17-induced Act1-mediated signaling is critical for cuprizone-induced demyelination |
Q24338636 | IL-23 is increased in dendritic cells in multiple sclerosis and down-regulation of IL-23 by antisense oligos increases dendritic cell IL-10 production |
Q37085543 | IL-7 promotes T(H)1 development and serum IL-7 predicts clinical response to interferon-β in multiple sclerosis |
Q47680353 | IL7RA haplotype-associated alterations in cellular immune function and gene expression patterns in multiple sclerosis. |
Q33998401 | IL7Rα contributes to experimental autoimmune encephalomyelitis through altered T cell responses and nonhematopoietic cell lineages |
Q36416533 | Identification of a novel mechanism of action of fingolimod (FTY720) on human effector T cell function through TCF-1 upregulation |
Q33378475 | Identification of a novel risk locus for multiple sclerosis at 13q31.3 by a pooled genome-wide scan of 500,000 single nucleotide polymorphisms |
Q33953320 | Identification of an IL-27/osteopontin axis in dendritic cells and its modulation by IFN-gamma limits IL-17-mediated autoimmune inflammation |
Q34835462 | Identification of biomarkers in cerebrospinal fluid and serum of multiple sclerosis patients by immunoproteomics approach |
Q38902001 | Identification of human herpesviruses 1 to 8 in Tunisian multiple sclerosis patients and healthy blood donors |
Q34599027 | Imatinib ameliorates neuroinflammation in a rat model of multiple sclerosis by enhancing blood-brain barrier integrity and by modulating the peripheral immune response |
Q91787847 | Immune and central nervous system-related miRNAs expression profiling in monocytes of multiple sclerosis patients |
Q36151968 | Immune modulating peptides for the treatment and suppression of multiple sclerosis |
Q36841506 | Immune modulation and increased neurotrophic factor production in multiple sclerosis patients treated with testosterone |
Q52893492 | Immune monitoring of Trichuris suis egg therapy in multiple sclerosis patients. |
Q33886414 | Immune regulatory CNS-reactive CD8+T cells in experimental autoimmune encephalomyelitis |
Q82709302 | Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study |
Q48965109 | Immune-modulation and properties of absorption and blood brain barrier permeability of 1,8-naphthyridine derivatives |
Q36280862 | Immunologic and MRI markers of the therapeutic effect of IFN-β-1a in relapsing-remitting MS. |
Q80426447 | Immunology of multiple sclerosis |
Q27016045 | Immunology of neuromyelitis optica: a T cell-B cell collaboration |
Q38937346 | Immunometabolism and autoimmunity |
Q36067334 | Immunomodulation Mechanism of Antidepressants: Interactions between Serotonin/Norepinephrine Balance and Th1/Th2 Balance |
Q34448370 | Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity |
Q36577275 | Immunopathogenesis and immunotherapy of multiple sclerosis |
Q36832873 | Immunopathogenesis of multiple sclerosis |
Q36198757 | Immunopathological patterns from EAE and Theiler's virus infection: Is multiple sclerosis a homogenous 1-stage or heterogenous 2-stage disease? |
Q26745562 | Impact of Exercise on Innate Immunity in Multiple Sclerosis Progression and Symptomatology |
Q34093041 | Impact of HLA-G analysis in prevention, diagnosis and treatment of pathological conditions |
Q34622205 | Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial |
Q34538700 | Impaired IFN-γ production and proliferation of NK cells in multiple sclerosis |
Q34077547 | Impaired neurosteroid synthesis in multiple sclerosis. |
Q90263600 | Impairment of Mitochondrial Redox Status in Peripheral Lymphocytes of Multiple Sclerosis Patients |
Q57798606 | Increased CD74 binding and EAE treatment efficacy of a modified DRα1 molecular construct |
Q33490992 | Increased numbers of IL-7 receptor molecules on CD4+CD25-CD107a+ T-cells in patients with autoimmune diseases affecting the central nervous system |
Q37121507 | Increased osteopontin expression in dendritic cells amplifies IL-17 production by CD4+ T cells in experimental autoimmune encephalomyelitis and in multiple sclerosis |
Q34971488 | Induction of encephalitis in rhesus monkeys infused with lymphocryptovirus-infected B-cells presenting MOG(34-56) peptide |
Q30908652 | Infection risk in patients on multiple sclerosis therapeutics |
Q54635826 | Inhibition of reactive astrocytosis in established experimental autoimmune encephalomyelitis favors infiltration by myeloid cells over T cells and enhances severity of disease. |
Q37591113 | Inhibition of the immunoproteasome ameliorates experimental autoimmune encephalomyelitis |
Q44497613 | Inhibitor IκBα promoter functional polymorphisms in patients with multiple sclerosis |
Q38156767 | Initial immunopathogenesis of multiple sclerosis: innate immune response. |
Q38118170 | Innate immune responses in the CNS: role of toll-like receptors, mechanisms, and therapeutic opportunities in multiple sclerosis |
Q63363253 | Innate, innate-like and adaptive lymphocytes in the pathogenesis of MS and EAE |
Q39622523 | Integration of MicroRNA databases to study MicroRNAs associated with multiple sclerosis. |
Q34544891 | Interferon regulatory factor (IRF) 3 is critical for the development of experimental autoimmune encephalomyelitis |
Q51025796 | Interferon-beta therapy in multiple sclerosis: the short-term and long-term effects on the patients' individual gene expression in peripheral blood. |
Q79613933 | Interferon-beta therapy reduces CD4+ and CD8+ T-cell reactivity in multiple sclerosis |
Q34482841 | Interferon-β induces hepatocyte growth factor in monocytes of multiple sclerosis patients |
Q34680345 | Interferon‐β inhibits toll‐like receptor 9 processing in multiple sclerosis |
Q80335293 | Interleukin 17-producing T-helper cells and autoimmune diseases: time for a paradigm shift? |
Q24681662 | Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis |
Q34937637 | Interleukin-1β causes excitotoxic neurodegeneration and multiple sclerosis disease progression by activating the apoptotic protein p53. |
Q35780751 | Interleukin-22 is increased in multiple sclerosis patients and targets astrocytes |
Q42282484 | Interleukin-6 as a mechanism for the adverse effects of social stress on acute Theiler's virus infection. |
Q36315737 | Interleukin-7 is required for CD4(+) T cell activation and autoimmune neuroinflammation. |
Q36571278 | Intermittent feeding attenuates clinical course of experimental autoimmune encephalomyelitis in C57BL/6 mice |
Q42131303 | Internalization and presentation of myelin antigens by the brain endothelium guides antigen-specific T cell migration |
Q59355260 | Intrathecal B Cells in MS Have Significantly Greater Lymphangiogenic Potential Compared to B Cells Derived From Non-MS Subjects |
Q36108869 | Intrathecal T-cell clonal expansions in patients with multiple sclerosis |
Q36359691 | Intravenous immunoglobulin and multiple sclerosis |
Q28083069 | Invariant natural killer T cells and their ligands: focus on multiple sclerosis |
Q26774642 | Involvement of CD8(+) T Cells in Multiple Sclerosis |
Q38962165 | Is monocyte- and macrophage-derived tissue transglutaminase involved in inflammatory processes? |
Q91994956 | Is multiple sclerosis progression associated with the HLA-DR15 haplotype? |
Q55347930 | Is there a link between inflammation and fatigue in multiple sclerosis? |
Q42341307 | Is there a place for 'immuno' in the immunotherapy of multiple sclerosis? |
Q37605028 | Isolation and th17 differentiation of naïve CD4 T lymphocytes. |
Q59349868 | KIR2DL4-HLAG interaction at human NK cell-oligodendrocyte interfaces regulates IFN-γ-mediated effects |
Q36768701 | Kappa opioid receptor activation alleviates experimental autoimmune encephalomyelitis and promotes oligodendrocyte-mediated remyelination. |
Q37085783 | Lame ducks or fierce creatures? The role of oligodendrocytes in multiple sclerosis |
Q33528993 | Learning from nature: pregnancy changes the expression of inflammation-related genes in patients with multiple sclerosis |
Q34249594 | Leptin neutralization interferes with pathogenic T cell autoreactivity in autoimmune encephalomyelitis |
Q92051349 | Let-7f-5p suppresses Th17 differentiation via targeting STAT3 in multiple sclerosis |
Q84622973 | Leuprolide acetate, a GnRH agonist, improves experimental autoimmune encephalomyelitis: a possible therapy for multiple sclerosis |
Q47616930 | Lewis Rat Model of Experimental Autoimmune Encephalomyelitis |
Q92432120 | Lipid profile of cerebrospinal fluid in multiple sclerosis patients: a potential tool for diagnosis |
Q36887316 | Lipids and lipid-reactive antibodies as biomarkers for multiple sclerosis |
Q33761191 | Lipocalin-2 protein deficiency ameliorates experimental autoimmune encephalomyelitis: the pathogenic role of lipocalin-2 in the central nervous system and peripheral lymphoid tissues |
Q37245952 | Lithium prevents and ameliorates experimental autoimmune encephalomyelitis |
Q28075478 | Live Imaging of Immune Responses in Experimental Models of Multiple Sclerosis |
Q37304845 | Liver X receptor agonist regulation of Th17 lymphocyte function in autoimmunity |
Q38101013 | Liver X receptors, nervous system, and lipid metabolism. |
Q34409257 | Long-term daclizumab therapy in relapsing-remitting multiple sclerosis |
Q37696989 | Long-term safety and efficacy of natalizumab in relapsing-remitting multiple sclerosis: impact on quality of life. |
Q49164654 | Long-term safety and real-world effectiveness of fingolimod in relapsing multiple sclerosis |
Q60301285 | Longitudinal changes in the expression of IL-33 and IL-33 regulated genes in relapsing remitting MS |
Q34291918 | Loss of AMPK exacerbates experimental autoimmune encephalomyelitis disease severity |
Q47963320 | Loss of Gas6 and Axl signaling results in extensive axonal damage, motor deficits, prolonged neuroinflammation, and less remyelination following cuprizone exposure. |
Q36637406 | Loss of electrostatic cell-surface repulsion mediates myelin membrane adhesion and compaction in the central nervous system |
Q47999107 | Loss of β-arrestin 2 exacerbates experimental autoimmune encephalomyelitis with reduced number of Foxp3+ CD4+ regulatory T cells |
Q36590210 | Lymphocytes with cytotoxic activity induce rapid microtubule axonal destabilization independently and before signs of neuronal death |
Q36430136 | MHC class II proteins and disease: a structural perspective |
Q36342130 | MHC mismatch results in neural progenitor cell rejection following spinal cord transplantation in a model of viral-induced demyelination |
Q46234913 | MIF and D-DT are potential disease severity modifiers in male MS subjects |
Q34370104 | MOG transmembrane and cytoplasmic domains contain highly stimulatory T-cell epitopes in MS. |
Q36154032 | MP4- and MOG:35-55-induced EAE in C57BL/6 mice differentially targets brain, spinal cord and cerebellum |
Q33233907 | MRI-guided immunotherapy development for multiple sclerosis in a primate |
Q35601282 | MS in South Asians in England: early disease onset and novel pattern of myelin autoimmunity |
Q90564159 | Machine learning analysis of motor evoked potential time series to predict disability progression in multiple sclerosis |
Q35928741 | Macrophage migration inhibitory factor promotes resistance to glucocorticoid treatment in EAE. |
Q36013705 | Mast Cells are Important Modifiers of Autoimmune Disease: With so Much Evidence, Why is There Still Controversy? |
Q37578015 | Mast cell modulation of the immune response |
Q92030412 | Mdivi-1, a mitochondrial fission inhibitor, modulates T helper cells and suppresses the development of experimental autoimmune encephalomyelitis |
Q33740585 | MeCP2 reinforces STAT3 signaling and the generation of effector CD4+ T cells by promoting miR-124-mediated suppression of SOCS5. |
Q37414117 | Mechanisms of oligodendrocyte regeneration from ventricular-subventricular zone-derived progenitor cells in white matter diseases |
Q90453420 | Mechanisms of pathophysiology of blood vessels in patients with multiple sclerosis treated with ozone therapy: a systematic review |
Q29617977 | Mechanisms underlying inflammation in neurodegeneration |
Q51825411 | Melanoma inhibitor of apoptosis protein (ML-IAP) specific cytotoxic T lymphocytes cross-react with an epitope from the auto-antigen SS56. |
Q36061629 | Melatonin Contributes to the Seasonality of Multiple Sclerosis Relapses |
Q37354623 | Membrane bound IL-15 is increased on CD14 monocytes in early stages of MS. |
Q58709181 | Memory B Cells Activate Brain-Homing, Autoreactive CD4 T Cells in Multiple Sclerosis |
Q36652220 | Mesenchymal stem cells are mobilized from the bone marrow during inflammation |
Q34247703 | Metformin attenuated the autoimmune disease of the central nervous system in animal models of multiple sclerosis |
Q28575785 | Methylprednisolone inhibits IFN-gamma and IL-17 expression and production by cells infiltrating central nervous system in experimental autoimmune encephalomyelitis |
Q37728572 | MiR-126 and miR-126* regulate shear-resistant firm leukocyte adhesion to human brain endothelium |
Q28509195 | MicroRNA miR-326 regulates TH-17 differentiation and is associated with the pathogenesis of multiple sclerosis |
Q38645580 | MicroRNA-181 Variants Regulate T Cell Phenotype in the Context of Autoimmune Neuroinflammation. |
Q35974243 | MicroRNA-301a regulation of a T-helper 17 immune response controls autoimmune demyelination |
Q33243924 | Microarray analysis identifies a set of CXCR3 and CCR2 ligand chemokines as early IFNbeta-responsive genes in peripheral blood lymphocytes in vitro: an implication for IFNbeta-related adverse effects in multiple sclerosis |
Q22252213 | Microbial view of central nervous system autoimmunity |
Q36995320 | Microglia play a major role in direct viral-induced demyelination |
Q38131730 | Microglia-mediated neuroinflammation is an amplifier of virus-induced neuropathology |
Q34124465 | Microwave & magnetic (M2) proteomics reveals CNS-specific protein expression waves that precede clinical symptoms of experimental autoimmune encephalomyelitis. |
Q30435441 | Migration of engrafted neural stem cells is mediated by CXCL12 signaling through CXCR4 in a viral model of multiple sclerosis |
Q28265793 | Mini review: immune response to myelin-derived sulfatide and CNS-demyelination |
Q91982232 | Mitochondrial Dysfunction and Multiple Sclerosis |
Q92365106 | Mitochondrial functionality and metabolism in T cells from progressive multiple sclerosis patients |
Q36286370 | Mitoxantrone repression of astrocyte activation: relevance to multiple sclerosis |
Q37119854 | Modeling the heterogeneity of multiple sclerosis in animals |
Q30483471 | Models of autoimmune demyelination in the central nervous system: on the way to translational medicine |
Q48630939 | Modulating the immune system through nanotechnology. |
Q37007219 | Modulation by melatonin of the pathogenesis of inflammatory autoimmune diseases. |
Q36832884 | Molecular "negativity" may underlie multiple sclerosis: role of the myelin basic protein family in the pathogenesis of MS. |
Q48354362 | Molecular Genetic and Epigenetic Basis of Multiple Sclerosis |
Q55617506 | Molecular Mechanisms of Oligodendrocyte Regeneration in White Matter-Related Diseases. |
Q35197096 | Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders |
Q33753720 | Molecular mechanisms of T-cell receptor and costimulatory molecule ligation/blockade in autoimmune disease therapy |
Q24613288 | Molecular mimicry as an inducing trigger for CNS autoimmune demyelinating disease |
Q36885184 | Molecular targets for disrupting leukocyte trafficking during multiple sclerosis |
Q37814815 | Monoclonal antibody therapy in multiple sclerosis: Paradigm shifts and emerging challenges |
Q30840308 | Monocyte behaviour and tissue transglutaminase expression during experimental autoimmune encephalomyelitis in transgenic CX3CR1gfp/gfp mice |
Q90049708 | Mucosal Administration of E-selectin Limits Disability in Models of Multiple Sclerosis |
Q37788598 | Multiple Sclerosis Therapies: Molecular Mechanisms and Future |
Q41525680 | Multiple Sclerosis Treatments Affect Monocyte-Derived Microvesicle Production |
Q39420793 | Multiple Sclerosis: Immunopathology and Treatment Update |
Q64912153 | Multiple Sclerosis: New Aspects of Immunopathogenesis. |
Q37785133 | Multiple functional targets of the immunoregulatory activity of galectin-1: Control of immune cell trafficking, dendritic cell physiology, and T-cell fate. |
Q37776054 | Multiple sclerosis and cerebral endothelial dysfunction: Mechanisms |
Q43136157 | Multiple sclerosis and the blood-central nervous system barrier |
Q36832911 | Multiple sclerosis as a painful disease |
Q43635768 | Multiple sclerosis associates with LILRA3 deletion in Spanish patients. |
Q37040077 | Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls |
Q37150347 | Multiple sclerosis, blood flow, and CSF circulation |
Q36032150 | Multiple sclerosis: Molecular mimicry of an antimyelin HLA class I restricted T-cell receptor |
Q36915907 | Multiple sclerosis: a complicated picture of autoimmunity. |
Q43125787 | Multiple sclerosis: closing in on an oral treatment. |
Q84390184 | Multiple sclerosis: human model for EAE? |
Q35683398 | Multiple sclerosis: myeloperoxidase immunoradiology improves detection of acute and chronic disease in experimental model. |
Q34342662 | Multiple sclerosis: overview of disease-modifying agents |
Q79196544 | Multiple sclerosis: putting two and two together |
Q60949833 | Multiplex Matrix Metalloproteinases Analysis in the Cerebrospinal Fluid Reveals Potential Specific Patterns in Multiple Sclerosis Patients |
Q35891605 | Myelin Basic Protein-Induced Production of Tumor Necrosis Factor-α and Interleukin-6, and Presentation of the Immunodominant Peptide MBP85-99 by B Cells from Patients with Relapsing-Remitting Multiple Sclerosis |
Q38156034 | Myelin architecture: zippering membranes tightly together |
Q36562052 | Myelin oligodendrocyte glycoprotein (MOG35-55)-induced experimental autoimmune encephalomyelitis is ameliorated in interleukin-32 alpha transgenic mice |
Q80171702 | Myelin-phagocytosing macrophages in isolated sciatic and optic nerves reveal a unique reactive phenotype |
Q35146791 | Myelin-phagocytosing macrophages modulate autoreactive T cell proliferation |
Q52576677 | NKG2D-mediated cytotoxicity toward oligodendrocytes suggests a mechanism for tissue injury in multiple sclerosis. |
Q40786516 | Nano- and micro-based systems for immunotolerance induction in multiple sclerosis |
Q57486472 | Naringenin Modifies the Development of Lineage-Specific Effector CD4 T Cells |
Q34994463 | Natalizumab restores aberrant miRNA expression profile in multiple sclerosis and reveals a critical role for miR-20b |
Q37213706 | Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells. |
Q37124504 | Natural killer cells and their receptors in multiple sclerosis |
Q36166679 | Natural triterpenes modulate immune-inflammatory markers of experimental autoimmune encephalomyelitis: therapeutic implications for multiple sclerosis |
Q37343069 | Naturally presented peptides on major histocompatibility complex I and II molecules eluted from central nervous system of multiple sclerosis patients |
Q91338016 | Nav1.5 in astrocytes plays a sex-specific role in clinical outcomes in a mouse model of multiple sclerosis |
Q35484427 | Neonatal induction of myelin-specific Th1/Th17 immunity does not result in experimental autoimmune encephalomyelitis and can protect against the disease in adulthood |
Q33821451 | Neonatal maternal separation alters immune, endocrine, and behavioral responses to acute Theiler's virus infection in adult mice |
Q26864449 | Neuroendocrine immunoregulation in multiple sclerosis |
Q36228999 | Neurofascin as a novel target for autoantibody-mediated axonal injury |
Q37424844 | Neuron-glia crosstalk in health and disease: fractalkine and CX3CR1 take centre stage |
Q33893135 | Neuronal I kappa B kinase beta protects mice from autoimmune encephalomyelitis by mediating neuroprotective and immunosuppressive effects in the central nervous system |
Q48380050 | Neuronal degeneration in a viral model of multiple sclerosis |
Q36869524 | Neuropathic pain in animal models of nervous system autoimmune diseases |
Q24645165 | Neuroprotection and remyelination after autoimmune demyelination in mice that inducibly overexpress CXCL1 |
Q27023974 | Neuroprotective effects of estrogens and androgens in CNS inflammation and neurodegeneration |
Q84080843 | Neuroprotective role of fibroblast growth factor-2 in experimental autoimmune encephalomyelitis |
Q34389528 | New approaches in the management of multiple sclerosis |
Q37057309 | New developments in understanding and treating neuroinflammation. |
Q34466301 | Niacin activates the PI3K/Akt cascade via PKC- and EGFR-transactivation-dependent pathways through hydroxyl-carboxylic acid receptor 2. |
Q24645400 | Nitric oxide and peroxynitrite in health and disease |
Q39010894 | Nogo-A Antibodies for Progressive Multiple Sclerosis |
Q28742885 | Nogo-receptors NgR1 and NgR2 do not mediate regulation of CD4 T helper responses and CNS repair in experimental autoimmune encephalomyelitis |
Q33507097 | Non-Linear Optical Imaging of Obesity-Related Health Risks: Review |
Q55518857 | Non-lesional cerebellar damage in patients with clinically isolated syndrome: DTI measures predict early conversion into clinically definite multiple sclerosis. |
Q92709805 | Non-parametric combination analysis of multiple data types enables detection of novel regulatory mechanisms in T cells of multiple sclerosis patients |
Q37952793 | Notch and inflammatory T-cell response: new developments and challenges |
Q34039982 | Notes on the epidemiology of multiple sclerosis, with special reference to dietary habits |
Q40694500 | Novel Function of Extracellular Matrix Protein 1 in Suppressing Th17 Cell Development in Experimental Autoimmune Encephalomyelitis. |
Q47948774 | Novel feedback loop between M2 macrophages/microglia and regulatory B cells in estrogen-protected EAE mice. |
Q37781515 | Nuclear Receptors, Inflammation, and Neurodegenerative Diseases |
Q27314385 | Nuclear receptor NR4A2 orchestrates Th17 cell-mediated autoimmune inflammation via IL-21 signalling |
Q39110118 | Nutrition and fasting mimicking diets in the prevention and treatment of autoimmune diseases and immunosenescence |
Q50644022 | OMIP-033: A comprehensive single step staining protocol for human T- and B-cell subsets. |
Q42622912 | OSP/claudin-11-induced EAE in mice is mediated by pathogenic T cells primarily governed by OSP192Y residue of major encephalitogenic region OSP179-207. |
Q90050581 | Obesity Promotes EAE Through IL-6 and CCL-2-Mediated T Cells Infiltration |
Q36598778 | Obeticholic acid, a synthetic bile acid agonist of the farnesoid X receptor, attenuates experimental autoimmune encephalomyelitis |
Q61811854 | Ocrelizumab Depletes CD20⁺ T Cells in Multiple Sclerosis Patients |
Q35954507 | Olig1 function is required for remyelination potential of transplanted neural progenitor cells in a model of viral-induced demyelination |
Q48853057 | Oligoclonal myelin-reactive T-cell infiltrates derived from multiple sclerosis lesions are enriched in Th17 cells. |
Q81083982 | Oligodendrocyte-specific protein is encephalitogenic in rhesus macaques and induces specific demyelination of the optic nerve |
Q37568350 | Opposing Functions of Microglial and Macrophagic TNFR2 in the Pathogenesis of Experimental Autoimmune Encephalomyelitis. |
Q56914273 | Opposing effects of HLA class I molecules in tuning autoreactive CD8+ T cells in multiple sclerosis |
Q28076588 | Optical Coherence Tomography and Magnetic Resonance Imaging in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder |
Q91843413 | Optimal response to dimethyl fumarate is mediated by a reduction of Th1-like Th17 cells after 3 months of treatment |
Q41673047 | Oral Administration of the Probiotic Strain Escherichia coli Nissle 1917 Reduces Susceptibility to Neuroinflammation and Repairs Experimental Autoimmune Encephalomyelitis-Induced Intestinal Barrier Dysfunction |
Q46412279 | Oral administration of the nitroxide radical TEMPOL exhibits immunomodulatory and therapeutic properties in multiple sclerosis models |
Q36830152 | Oral disease-modifying treatments for multiple sclerosis: the story so far. |
Q36716680 | Orphan nuclear receptor NR4A2 expressed in T cells from multiple sclerosis mediates production of inflammatory cytokines |
Q24337079 | Oxidative stress-induced signaling pathways implicated in the pathogenesis of Parkinson's disease |
Q34094680 | PD-L1 is increased in the spinal cord and infiltrating lymphocytes in experimental allergic encephalomyelitis |
Q24296651 | PI3K delta and PI3K gamma: partners in crime in inflammation in rheumatoid arthritis and beyond? |
Q34428066 | PI3Kγ drives priming and survival of autoreactive CD4(+) T cells during experimental autoimmune encephalomyelitis. |
Q33591700 | PIF* promotes brain re-myelination locally while regulating systemic inflammation- clinically relevant multiple sclerosis M.smegmatis model |
Q36750245 | PINK1 Deficiency Enhances Inflammatory Cytokine Release from Acutely Prepared Brain Slices |
Q36356190 | PRDX6 controls multiple sclerosis by suppressing inflammation and blood brain barrier disruption |
Q37626083 | Paeoniflorin Ameliorates Experimental Autoimmune Encephalomyelitis via Inhibition of Dendritic Cell Function and Th17 Cell Differentiation |
Q35510088 | Paranodal myelin retraction in relapsing experimental autoimmune encephalomyelitis visualized by coherent anti-Stokes Raman scattering microscopy |
Q37210758 | Partial MHC class II constructs inhibit MIF/CD74 binding and downstream effects |
Q80285957 | Passive induction of experimental allergic encephalomyelitis |
Q36961069 | Pathogenesis of acute and chronic central nervous system infection with variants of mouse hepatitis virus, strain JHM. |
Q38008365 | Pathogenic CD8 T cells in multiple sclerosis and its experimental models |
Q81437623 | Pathogenic T cells in MOBP-induced murine EAE are predominantly focused to recognition of MOBP21F and MOBP27P epitopic residues |
Q57465762 | Pathological transitions in myelin membranes driven by environmental and multiple sclerosis conditions |
Q36965753 | Pathways and gene networks mediating the regulatory effects of cannabidiol, a nonpsychoactive cannabinoid, in autoimmune T cells |
Q42418046 | Patients with relapsing-remitting multiple sclerosis have normal Treg function when cells expressing IL-7 receptor alpha-chain are excluded from the analysis |
Q64072217 | Perfluorinated substances, risk factors for multiple sclerosis and cellular immune activation |
Q38654791 | Peripheral blood lymphocytes immunophenotyping predicts disease activity in clinically isolated syndrome patients |
Q36528981 | Peroxisome proliferator-activated receptor-alpha agonist fenofibrate regulates IL-12 family cytokine expression in the CNS: relevance to multiple sclerosis |
Q36528985 | Peroxisome proliferator-activated receptor-gamma agonists suppress the production of IL-12 family cytokines by activated glia |
Q38128224 | Perspectives of the relationship between IL-7 and autoimmune diseases. |
Q35949095 | Pharmacokinetics of Py-Im polyamides depend on architecture: cyclic versus linear |
Q48784902 | Phospholipase D1 mediates lymphocyte adhesion and migration in experimental autoimmune encephalomyelitis |
Q24311954 | Phosphorylation of U24 from Human Herpes Virus type 6 (HHV-6) and its potential role in mimicking myelin basic protein (MBP) in multiple sclerosis |
Q34807106 | Photobiomodulation induced by 670 nm light ameliorates MOG35-55 induced EAE in female C57BL/6 mice: a role for remediation of nitrosative stress |
Q37100959 | Pituitary adenylyl cyclase-activating polypeptide is an intrinsic regulator of Treg abundance and protects against experimental autoimmune encephalomyelitis |
Q24236418 | Plasma exchange for multiple sclerosis |
Q94398401 | Plasma exchange for multiple sclerosis |
Q36567230 | Plasmacytoid dendritic cells and immunotherapy in multiple sclerosis. |
Q34117705 | Plasmacytoid dendritic cells in multiple sclerosis: chemokine and chemokine receptor modulation by interferon-beta |
Q30977483 | Polymorphonuclear Cell Functional Impairment in Relapsing Remitting Multiple Sclerosis Patients: Preliminary Data |
Q33768549 | Potent and orally efficacious bisthiazole-based histone deacetylase inhibitors |
Q37957892 | Potential impact of B cells on T cell function in multiple sclerosis |
Q36781267 | Potential of urinary metabolites for diagnosing multiple sclerosis |
Q38930119 | Potential targeting of B7-H4 for the treatment of cancer. |
Q34624709 | Potential triggers of MS |
Q28553993 | Preclinical Metabolism, Pharmacokinetics and In Vivo Analysis of New Blood-Brain-Barrier Penetrant Fingolimod Analogues: FTY720-C2 and FTY720-Mitoxy |
Q34105985 | Preliminary study: treatment with intramuscular interferon beta-1a results in increased levels of IL-12Rβ2+ and decreased levels of IL23R+ CD4+ T - Lymphocytes in multiple sclerosis |
Q37081321 | Prevention of autoimmune disease by induction of tolerance to Toll-like receptor 7 |
Q52145132 | Production of IL-27 in multiple sclerosis lesions by astrocytes and myeloid cells: Modulation of local immune responses. |
Q48820703 | Progressive tumefactive inflammatory central nervous system demyelinating disease in an acquired immunodeficiency syndrome patient treated with highly active antiretroviral therapy |
Q37362453 | Promiscuous drugs as therapeutics for chemokine receptors |
Q34828914 | Promotion of remyelination by adipose mesenchymal stem cell transplantation in a cuprizone model of multiple sclerosis |
Q36604126 | Protein-Based Classifier to Predict Conversion from Clinically Isolated Syndrome to Multiple Sclerosis |
Q36228251 | Proteinase-activated receptor 2 modulates neuroinflammation in experimental autoimmune encephalomyelitis and multiple sclerosis |
Q35135555 | Psyche and soma: New insights into the connection |
Q31014036 | Purely systemically active anti-inflammatory treatments are adequate to control multiple sclerosis |
Q43113841 | Quantified CSF antibody reactivity against myelin in multiple sclerosis |
Q64953964 | Radon Therapy for Autoimmune Diseases Pemphigus and Diabetes: 2 Case Reports. |
Q37401147 | Reactive astrocytes form scar-like perivascular barriers to leukocytes during adaptive immune inflammation of the CNS. |
Q28740839 | Reassessment of blood gene expression markers for the prognosis of relapsing-remitting multiple sclerosis |
Q24812119 | Recognition of conserved amino acid motifs of common viruses and its role in autoimmunity |
Q36976664 | Recognition of self-peptide-MHC complexes by autoimmune T-cell receptors |
Q39302587 | Reconstitution of immune cell populations in multiple sclerosis patients after autologous stem cell transplantation. |
Q34053766 | Reduction in Healthcare and Societal Resource Utilization Associated with Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis : Analysis of Economic Data from the CLARITY Study |
Q35744057 | Regional Distribution and Evolution of Gray Matter Damage in Different Populations of Multiple Sclerosis Patients |
Q34645439 | Regulation of Th1/Th17 cytokines and IDO gene expression by inhibition of calpain in PBMCs from MS patients |
Q85209692 | Regulation of cannabinoid receptor gene expression and endocannabinoid levels in lymphocyte subsets by interferon-β: a longitudinal study in multiple sclerosis patients |
Q38909429 | Regulation of suppressors of cytokine signaling as a therapeutic approach in autoimmune diseases, with an emphasis on multiple sclerosis |
Q36039356 | Regulation of the severity of neuroinflammation and demyelination by TLR-ASK1-p38 pathway |
Q39032832 | Regulatory Functions of Natural Killer Cells in Multiple Sclerosis. |
Q30574747 | Relapsing-remitting central nervous system autoimmunity mediated by GFAP-specific CD8 T cells |
Q37619855 | Relevance of molecular mimicry in the mediation of infectious myocarditis |
Q61443079 | Remyelination promoting therapies in multiple sclerosis animal models: a systematic review and meta-analysis |
Q81461292 | Requirement of the Fc receptor common gamma-chain for gamma delta T cell-mediated promotion of murine experimental autoimmune encephalomyelitis |
Q36700407 | Resveratrol (trans-3,5,4'-trihydroxystilbene) ameliorates experimental allergic encephalomyelitis, primarily via induction of apoptosis in T cells involving activation of aryl hydrocarbon receptor and estrogen receptor |
Q36494558 | Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis. |
Q30278584 | Revisiting the Mechanisms of CNS Immune Privilege |
Q33849373 | Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients. |
Q36832863 | Role of B cells in pathogenesis of multiple sclerosis |
Q28298240 | Role of IL-15 in immune-mediated and infectious diseases |
Q26795528 | Role of T cell-glial cell interactions in creating and amplifying central nervous system inflammation and multiple sclerosis disease symptoms |
Q35721897 | Role of a Novel Human Leukocyte Antigen-DQA1*01:02;DRB1*15:01 Mixed Isotype Heterodimer in the Pathogenesis of "Humanized" Multiple Sclerosis-like Disease. |
Q38562775 | Role of autophagy in the pathogenesis of multiple sclerosis |
Q37735773 | Role of cytokines as mediators and regulators of microglial activity in inflammatory demyelination of the CNS. |
Q35206805 | Role of pathogens in multiple sclerosis |
Q38114422 | Role of regulatory T cells in pathogenesis and biological therapy of multiple sclerosis |
Q38384621 | Role of the innate and adaptive immune responses in the course of multiple sclerosis |
Q33787624 | Role of the innate immune system in the pathogenesis of multiple sclerosis |
Q37021687 | Role of toll-like receptors in multiple sclerosis |
Q27325607 | SJL mice infected with Acanthamoeba castellanii develop central nervous system autoimmunity through the generation of cross-reactive T cells for myelin antigens |
Q89865080 | STAT3 signaling in myeloid cells promotes pathogenic myelin-specific T cell differentiation and autoimmune demyelination |
Q35819291 | STAT4 controls GM-CSF production by both Th1 and Th17 cells during EAE. |
Q35244158 | Selected extracellular microRNA as potential biomarkers of multiple sclerosis activity--preliminary study |
Q39313856 | Semaphorin 7A as a Potential Therapeutic Target for Multiple Sclerosis |
Q37009992 | Serum Gelatinases Levels in Multiple Sclerosis Patients during 21 Months of Natalizumab Therapy. |
Q36562595 | Serum lipid antibodies are associated with cerebral tissue damage in multiple sclerosis |
Q33645392 | Sex-dependent treatment of chronic EAE with partial MHC class II constructs |
Q58784650 | Sex: A Significant Risk Factor for Neurodevelopmental and Neurodegenerative Disorders |
Q34673043 | Signaling via the RIP2 adaptor protein in central nervous system-infiltrating dendritic cells promotes inflammation and autoimmunity |
Q36298402 | Silencing of Abcc8 or inhibition of newly upregulated Sur1-Trpm4 reduce inflammation and disease progression in experimental autoimmune encephalomyelitis |
Q40882468 | Simulation of spread and control of lesions in brain |
Q47209789 | Simultaneous inference of phenotype-associated genes and relevant tissues from GWAS data via Bayesian integration of multiple tissue-specific gene networks. |
Q58326709 | Simvastatin inhibits secretion of Th17-polarizing cytokines and antigen presentation by DCs in patients with relapsing remitting multiple sclerosis |
Q36683168 | Sinomenine reduces iNOS expression via inhibiting the T-bet IFN-γ pathway in experimental autoimmune encephalomyelitis in rats |
Q39926496 | Smad7 in T cells drives T helper 1 responses in multiple sclerosis and experimental autoimmune encephalomyelitis |
Q36527783 | SncRNA (microRNA &snoRNA) opposite expression pattern found in multiple sclerosis relapse and remission is sex dependent. |
Q35489039 | Social disruption induced priming of CNS inflammatory response to Theiler's virus is dependent upon stress induced IL-6 release |
Q38204275 | Sphingosine-1 phosphate and central nervous system |
Q24683357 | Splice variation in the cytoplasmic domains of myelin oligodendrocyte glycoprotein affects its cellular localisation and transport |
Q37165311 | Statins' immunomodulatory potential against Th17 cell-mediated autoimmune response |
Q35902446 | Stepchild or Prodigy? Neuroprotection in Multiple Sclerosis (MS) Research |
Q89977191 | Strategies for Neuroprotection in Multiple Sclerosis and the Role of Calcium |
Q34651994 | Structural and dynamical insights on HLA-DR2 complexes that confer susceptibility to multiple sclerosis in Sardinia: a molecular dynamics simulation study |
Q36404007 | Structural basis for CD1d presentation of a sulfatide derived from myelin and its implications for autoimmunity |
Q27667717 | Structure of HLA-A*0301 in complex with a peptide of proteolipid protein: insights into the role of HLA-A alleles in susceptibility to multiple sclerosis |
Q27666863 | Structure of a TCR with high affinity for self-antigen reveals basis for escape from negative selection |
Q33947114 | Structure of a human autoimmune TCR bound to a myelin basic protein self-peptide and a multiple sclerosis-associated MHC class II molecule |
Q36228518 | Suppression of experimental autoimmune encephalomyelitis by extracellular adherence protein of Staphylococcus aureus |
Q40196823 | Suppression of microglial inflammatory activity by myelin phagocytosis: role of p47-PHOX-mediated generation of reactive oxygen species. |
Q42589482 | Synergistic activity of interleukin-17 and tumor necrosis factor-α enhances oxidative stress-mediated oligodendrocyte apoptosis |
Q37197381 | Synthetic retinoid AM80 inhibits Th17 cells and ameliorates experimental autoimmune encephalomyelitis |
Q34463760 | Systemic inflammation and the brain: novel roles of genetic, molecular, and environmental cues as drivers of neurodegeneration |
Q37174203 | Systems biology approaches for the study of multiple sclerosis |
Q43457921 | T helper cell type 1 (Th1), Th2 and Th17 responses to myelin basic protein and disease activity in multiple sclerosis |
Q33723154 | T-cell based immunotherapy in experimental autoimmune encephalomyelitis and multiple sclerosis |
Q50898570 | T-cell responses after haematopoietic stem cell transplantation for aggressive relapsing-remitting multiple sclerosis. |
Q30433284 | TASK1 modulates inflammation and neurodegeneration in autoimmune inflammation of the central nervous system |
Q34171867 | TCR recognition of peptide/MHC class II complexes and superantigens |
Q34418098 | TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab |
Q40157170 | TLR7 Signaling Regulates Th17 Cells and Autoimmunity: Novel Potential for Autoimmune Therapy |
Q42271141 | TLR7 signaling exacerbates CNS autoimmunity through downregulation of Foxp3+ Treg cells |
Q38706801 | Taming of macrophage and microglial cell activation by microRNA-124. |
Q35295564 | Targeting VIP and PACAP receptor signalling: new therapeutic strategies in multiple sclerosis |
Q35595092 | Targeting epidermal fatty acid binding protein for treatment of experimental autoimmune encephalomyelitis |
Q37730005 | Teriflunomide and its mechanism of action in multiple sclerosis |
Q37483670 | Th1 cells downregulate connexin 43 gap junctions in astrocytes via microglial activation. |
Q37805082 | Th17 cells in inflammation |
Q64075187 | The Association Between Vitamin D and Multiple Sclerosis Risk: 1,25(OH)D Induces Super-Enhancers Bound by VDR |
Q93015537 | The Contribution of Major Histocompatibility Complex Class II Genes to an Association with Autoimmune Diseases |
Q42280869 | The Effect of Levothyroxine on Serum Levels of Interleukin 10 and Interferon-gamma in Rat Model of Multiple Sclerosis |
Q37151141 | The Essential Role of Epstein-Barr Virus in the Pathogenesis of Multiple Sclerosis |
Q90393448 | The GPR17 Receptor-A Promising Goal for Therapy and a Potential Marker of the Neurodegenerative Process in Multiple Sclerosis |
Q47252742 | The Gut Microbiome in Neuromyelitis Optica |
Q54957634 | The HTLV-1 gp21 fusion peptide inhibits antigen specific T-cell activation in-vitro and in mice. |
Q53287408 | The Inflammasome Sensor, NLRP3, Regulates CNS Inflammation and Demyelination via Caspase-1 and Interleukin-18 |
Q38115525 | The Primate EAE Model Points at EBV-Infected B Cells as a Preferential Therapy Target in Multiple Sclerosis |
Q36216025 | The Role of Latently Infected B Cells in CNS Autoimmunity |
Q55431606 | The Role of Natural Killer Group 2, Member D in Chronic Inflammation and Autoimmunity. |
Q42820908 | The Role of Th17 in Neuroimmune Disorders: Target for CAM Therapy. Part II |
Q33595360 | The chemokine receptor antagonist, TAK-779, decreased experimental autoimmune encephalomyelitis by reducing inflammatory cell migration into the central nervous system, without affecting T cell function |
Q85174183 | The clinical course of EAE is reflected by the dynamics of the neuroantigen-specific T cell compartment in the blood |
Q34732881 | The clinical potential of blood-proteomics in multiple sclerosis |
Q33685823 | The complement cascade: Yin-Yang in neuroinflammation--neuro-protection and -degeneration |
Q37273745 | The complement inhibitor FUT-175 suppresses T cell autoreactivity in experimental autoimmune encephalomyelitis |
Q35294476 | The critical role of antigen-presentation-induced cytokine crosstalk in the central nervous system in multiple sclerosis and experimental autoimmune encephalomyelitis |
Q38500852 | The crucial role of mast cells in blood-brain barrier alterations |
Q37728840 | The cytokine milieu in the interplay of pathogenic Th1/Th17 cells and regulatory T cells in autoimmune disease |
Q92186838 | The dark side of antiviral T cell responses |
Q36420375 | The effect of vitamin A supplementation on stimulated T-cell proliferation with myelin oligodendrocyte glycoprotein in patients with multiple sclerosis. |
Q24648473 | The endocannabinoid system as an emerging target of pharmacotherapy |
Q34979322 | The epigenetics of autoimmunity |
Q37830018 | The human microbiome in multiple sclerosis: pathogenic or protective constituents? |
Q34776567 | The immunogenetics of multiple sclerosis |
Q37857982 | The immunopathophysiology of multiple sclerosis |
Q41859500 | The inflammatory footprints of alcohol-induced oxidative damage in neurovascular components |
Q34081672 | The lactic acid bacterium Pediococcus acidilactici suppresses autoimmune encephalomyelitis by inducing IL-10-producing regulatory T cells |
Q42484597 | The majority of infiltrating CD8 T lymphocytes in multiple sclerosis lesions is insensitive to enhanced PD-L1 levels on CNS cells. |
Q84281957 | The microRNA miR-23b suppresses IL-17-associated autoimmune inflammation by targeting TAB2, TAB3 and IKK-α |
Q28541466 | The orally available, synthetic ether lipid edelfosine inhibits T cell proliferation and induces a type I interferon response |
Q26770815 | The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects |
Q92463066 | The protective role of TBX21-1514T>C polymorphism in susceptibility to multiple sclerosis |
Q36171258 | The relevance of cortical lesions in patients with multiple sclerosis |
Q38172891 | The resolution of neuroinflammation in neurodegeneration: leukocyte recruitment via the choroid plexus. |
Q36474320 | The role of CD4+ T-cells in the development of MS. |
Q36474330 | The role of CD8+ T-cells in lesion formation and axonal dysfunction in multiple sclerosis |
Q52669235 | The role of TAM family receptors and ligands in the nervous system: From development to pathobiology. |
Q90518839 | The role of chemokines and chemokine receptors in multiple sclerosis |
Q34468304 | The role of immune cells, glia and neurons in white and gray matter pathology in multiple sclerosis. |
Q34087938 | The role of kinin receptors in preventing neuroinflammation and its clinical severity during experimental autoimmune encephalomyelitis in mice |
Q47093555 | The roles of RGMa-neogenin signaling in inflammation and angiogenesis |
Q38685035 | The search for the target antigens of multiple sclerosis, part 1: autoreactive CD4+ T lymphocytes as pathogenic effectors and therapeutic targets |
Q31122077 | The spectrum of neuromyelitis optica |
Q36027486 | The structural and functional role of myelin fast-migrating cerebrosides: pathological importance in multiple sclerosis. |
Q26824619 | The use of flow cytometry to assess a novel drug efficacy in multiple sclerosis |
Q24534346 | The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain |
Q36291069 | Therapeutic anti-integrin (alpha4 and alphaL) monoclonal antibodies: two-edged swords? |
Q33785953 | Therapeutic blockade of T-cell antigen receptor signal transduction and costimulation in autoimmune disease |
Q26991746 | Therapeutic potential of mesenchymal stem cells for oral and systemic diseases |
Q33610240 | Therapeutic potential of statins in multiple sclerosis: immune modulation, neuroprotection and neurorepair |
Q34053912 | Thiamine deficiency promotes T cell infiltration in experimental autoimmune encephalomyelitis: the involvement of CCL2 |
Q33851359 | Thrombotic processes in multiple sclerosis as manifestation of innate immune activation. |
Q35867011 | Time-Dependent Progression of Demyelination and Axonal Pathology in MP4-Induced Experimental Autoimmune Encephalomyelitis |
Q64085734 | Tissue Transglutaminase Appears in Monocytes and Macrophages but Not in Lymphocytes in White Matter Multiple Sclerosis Lesions |
Q38098448 | Towards clinical application of mesenchymal stem cells for treatment of neurological diseases of the central nervous system |
Q37780481 | Transgenic mouse models of multiple sclerosis |
Q36614273 | Translocator protein 18 kDa (TSPO) expression in multiple sclerosis patients |
Q37191628 | Transmethylation in immunity and autoimmunity |
Q46474640 | Transplantation of glial-committed progenitor cells into a viral model of multiple sclerosis induces remyelination in the absence of an attenuated inflammatory response |
Q89505804 | Treatment effects of fingolimod in multiple sclerosis: Selective changes in peripheral blood lymphocyte subsets |
Q28484146 | Treatment of autoimmune inflammation by a TLR7 ligand regulating the innate immune system |
Q46932120 | Treatment of multiple sclerosis with methylprednisolone and mitoxantrone modulates the expression of CXC chemokine receptors in PBMC. |
Q37884434 | Treatment of multiple sclerosis: current concepts and future perspectives |
Q36299378 | Treatment with MOG-DNA vaccines induces CD4+CD25+FoxP3+ regulatory T cells and up-regulates genes with neuroprotective functions in experimental autoimmune encephalomyelitis. |
Q43568427 | Tumor necrosis factor beta (TNF-β) NcoI polymorphism is associated with multiple sclerosis in Caucasian patients from Southern Brazil independently from HLA-DRB1. |
Q37486214 | Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) in central nervous system inflammation |
Q36635630 | Two discreet subsets of CD8 T cells modulate PLP(91-110) induced experimental autoimmune encephalomyelitis in HLA-DR3 transgenic mice |
Q30580359 | Two-photon imaging of remyelination of spinal cord axons by engrafted neural precursor cells in a viral model of multiple sclerosis |
Q39315038 | Type I interferon pathway in CNS homeostasis and neurological disorders. |
Q45720900 | Type I interferon potentiates T-cell receptor mediated induction of IL-10-producing CD4⁺ T cells. |
Q34188446 | Unraveling the complexities of cannabinoid receptor 2 (CB2) immune regulation in health and disease |
Q37257176 | Up-regulation of soluble Axl and Mer receptor tyrosine kinases negatively correlates with Gas6 in established multiple sclerosis lesions |
Q43437323 | Upregulation of β-1,4-galactosyltransferase I in rat spinal cord with experimental autoimmune encephalomyelitis |
Q35424431 | Uptake and presentation of myelin basic protein by normal human B cells |
Q88346915 | Urinary Urea, Uric Acid and Hippuric Acid as Potential Biomarkers in Multiple Sclerosis Patients |
Q37651099 | Urinary tract infections in multiple sclerosis: under-diagnosed and under-treated? A clinical audit at a large University Hospital |
Q35738486 | Use of Humanized Mice to Study the Pathogenesis of Autoimmune and Inflammatory Diseases |
Q35888466 | Use of the VH6-1 gene segment to code for anti-interleukin-18 autoantibodies in multiple sclerosis. |
Q37085898 | Vaccines for multiple sclerosis: progress to date |
Q33350182 | Variants of ST8SIA1 are associated with risk of developing multiple sclerosis |
Q59543708 | Variations of the perforin gene in patients with multiple sclerosis |
Q34750423 | Venous hemodynamics in neurological disorders: an analytical review with hydrodynamic analysis |
Q93079858 | Virgin Olive Oil and Health: Summary of the III International Conference on Virgin Olive Oil and Health Consensus Report, JAEN (Spain) 2018 |
Q35123080 | Vitamin D3 influence the Th1/Th2 ratio in C57BL/6 induced model of experimental autoimmune encephalomyelitis |
Q47639897 | Western lifestyle and immunopathology of multiple sclerosis |
Q30454634 | What went wrong? The flawed concept of cerebrospinal venous insufficiency. |
Q36257285 | Without nerves, immunology remains incomplete -in vivo veritas |
Q51890165 | [Atacicept: a new B lymphocyte-targeted therapy for multiple sclerosis]. |
Q82620795 | [Multiple sclerosis -- a channelopathy? Targeting ion channels and transporters in inflammatory neurodegeneration] |
Q83217436 | [Multiple sclerosis and exercise : effects of physical activity on the immune system] |
Q51958899 | [Targeting B cells in multiple sclerosis. Current concepts and strategies]. |
Q35539301 | beta2-integrins in demyelinating disease: not adhering to the paradigm |
Q36248231 | gammadelta T cells: the overlooked T-cell subset in demyelinating disease |
Q49139961 | miR-155-3p Drives the Development of Autoimmune Demyelination by Regulation of Heat Shock Protein 40. |
Q42182365 | miR26a modulates Th17/T reg balance in the EAE model of multiple sclerosis by targeting IL6. |
Q37871931 | miRNAs stem cell reprogramming for neuronal induction and differentiation |
Q35855614 | p150/95 (CD11c/CD18) expression is required for the development of experimental autoimmune encephalomyelitis |
Q35632530 | αβ T-cell receptors from multiple sclerosis brain lesions show MAIT cell-related features |
Search more.